• |
  • |
  • |
  • |
Donate

Project

MOUNTAINSIDE (0367-CL-1201)

Center:
Fiscal Year:
2024
Contact Information:
Project Description:
Title: MOUNTAINSIDE (0367-CL-1201): A randomized, double-blind, placebo-controlled adaptive phase 2/3 Study with open-label extension to assess the efficacy, safety and tolerability of ASP0367 in participants with primary mitochondrial myopathy Role: Site PI Funding: Astellas Pharma Inc. October 2021-present Summary: This is a randomized, double-blind, placebo-controlled, oral dose, adaptive phase 2/3 study with open-label extension to evaluate the efficacy, safety and tolerability of ASP0367 in participants with primary mitochondrial myopathy.
Keyword(s):
Core Function(s):
Performing Research or Evaluation, Continuing Education/Community Training
Area of Emphasis
Other
Target Audience:
Children/Adolescents with Disabilities/SHCN
Unserved or Under-served Populations:
Other
Primary Target Audience Geographic Descriptor:
National
Funding Source:
COVID-19 Related Data:
N/A